Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Increased to $33.00 by Analysts at The Goldman Sachs Group

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price upped by The Goldman Sachs Group from $29.00 to $33.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada lowered their price target on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform rating on the stock in a report on Friday, February 16th. JPMorgan Chase & Co. lowered their price target on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a neutral rating on the stock in a report on Friday, February 23rd. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Agios Pharmaceuticals in a report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of Hold and a consensus target price of $34.75.

Agios Pharmaceuticals Stock Down 0.1 %

Agios Pharmaceuticals stock traded down $0.04 on Friday, hitting $34.54. The company’s stock had a trading volume of 807,894 shares, compared to its average volume of 713,175. The firm has a market cap of $1.96 billion, a P/E ratio of -5.47 and a beta of 0.81. The company has a fifty day moving average price of $30.61 and a 200-day moving average price of $25.63. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $35.50.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.19. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 39.74%. The business’s revenue for the quarter was up 46.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.47) EPS. Analysts anticipate that Agios Pharmaceuticals will post -5.29 EPS for the current year.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider James William Burns sold 2,642 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares in the company, valued at approximately $1,124,251.26. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the sale, the director now owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,035 shares of company stock valued at $475,277. 4.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. Vanguard Group Inc. lifted its stake in Agios Pharmaceuticals by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock valued at $123,096,000 after buying an additional 59,851 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Agios Pharmaceuticals by 6.0% in the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock valued at $78,479,000 after purchasing an additional 200,000 shares during the last quarter. Rock Springs Capital Management LP increased its holdings in shares of Agios Pharmaceuticals by 0.9% in the third quarter. Rock Springs Capital Management LP now owns 2,710,061 shares of the biopharmaceutical company’s stock valued at $67,074,000 after purchasing an additional 23,894 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Agios Pharmaceuticals by 5.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock valued at $57,832,000 after acquiring an additional 137,873 shares during the period. Finally, First Trust Advisors LP boosted its position in shares of Agios Pharmaceuticals by 2.4% in the fourth quarter. First Trust Advisors LP now owns 1,818,643 shares of the biopharmaceutical company’s stock valued at $40,501,000 after acquiring an additional 43,476 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.